Pfizer Looks Like A Great Play At Current Valuations

Group 1 - Pfizer Inc. (NYSE: PFE) is identified as an attractive value play in the pharmaceutical sector due to its low relative valuation [1] - The analysis indicates that PFE has potential for growth, making it a compelling investment opportunity [1] Group 2 - The author expresses a personal interest in algorithmic trading and macroeconomic topics, particularly focusing on China [1] - The author's investment experience includes a conservative track record with a portfolio yield of 17.5% in 2020 and a nearly flat performance in 2022 [1] - The author has transitioned to a quantitative trading approach, achieving a portfolio yield of 12.84% last year with a beta of less than 0.6 [1]